Best Health Care Grants in American Samoa

The U.S. Department of Labor's Bureau of International Labor Affairs is offering approximately $5 million for a cooperative agreement to enhance labor standards in the critical minerals sector in Argentina and Chile. This initiative aims to support American workers and boost manufacturing competitiveness through improved labor enforcement and compliance in the supply chain of essential minerals like copper, lithium, and silver. The project will last three years and involve various stakeholders in the region.

The "Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)" aims to foster partnerships between NIH intramural and extramural researchers. This initiative supports translational research projects that bridge basic biological discoveries and clinical applications, enhancing health outcomes. By encouraging collaborations, it seeks to accelerate the development of new therapies and prevention strategies, leveraging unique NIH resources to strengthen scientific innovation and address critical disease processes.

The FY 2026 SNAP Earnings Verification Support Grant by USDA's Food and Nutrition Administration aims to enhance food assistance programs by supporting State agencies in verifying earned income electronically. With a funding pool of up to $38 million, the grants will help states explore various income verification services. This initiative is vital for improving the efficiency of SNAP operations and ensuring that eligible applicants receive the assistance they need effectively over a 24-month period.

This funding opportunity aims to enhance understanding of chemical-induced skin injuries, particularly those recognized as public health threats. The initiative encourages research focused on identifying commonalities in these injuries and exploring shared signaling pathways. By investigating therapeutic targets, this program seeks to develop effective medical countermeasures. Multiple application deadlines are set from 2025 to 2027, supporting diverse research proposals in this crucial area.

The HEAL Initiative aims to develop safe and effective non-addictive pain therapeutics. This funding opportunity encourages translational research to support drug discovery, focusing on assays, screening for hits, and initial characterization of potential therapeutic agents, including small molecules and biologics. Applications are due by 5 PM local time, with optional Letters of Intent recommended 30 days prior to the proposal deadline.

The Aging Research Dissertation Awards aim to enhance diversity in the scientific workforce by funding research on aging and related health conditions. The program encourages applicants from underrepresented backgrounds to apply for dissertation awards that align with the National Institutes of Health's strategic priorities. Key deadlines for applications include February 16, June 16, and October 16 for the years 2024 through 2026.

The Gabriella Miller Kids First Pediatric Research Program invites applications for whole genome sequencing of pediatric cohorts. This initiative aims to explore the genetic basis of childhood cancers and congenital anomalies, enhancing our understanding of their etiology. Researchers are encouraged to propose sequencing methods, including whole genome and exome sequencing, to investigate genetic contributions and associations with cancer risk. The resulting data will be integrated into the Kids First Data Resource for broader research collaboration.

This funding opportunity aims to enhance the development of medical products in rare diseases through innovative natural history studies. By generating high-quality data, the FDA seeks to bridge critical knowledge gaps and eliminate barriers in rare disease research. The initiative focuses on diseases with unmet needs, fostering significant impacts for those affected and facilitating the development of effective therapeutic solutions.

The NARMS Cooperative Agreement Program aims to enhance antibiotic resistance surveillance in retail food specimens. Funded by the FDA, this initiative strengthens the National Antimicrobial Resistance Monitoring System established in 1996. By improving detection methods and expanding sampling sites, the program seeks to protect public health and align with NARMS objectives, ultimately combating the growing threat of antibiotic resistance in food commodities.

The RFA-FD-23-001 funding opportunity aims to support clinical trials for orphan products targeting rare diseases. It focuses on evaluating the efficacy and safety of treatments to address unmet medical needs. By promoting innovative and collaborative trial designs, the FDA seeks to enhance the approval rates of effective therapies for rare conditions, ultimately benefiting patients and advancing drug development in this critical area.

The CCRP Initiative invites applications for basic research on chemical threats affecting the nervous system, including chemical warfare agents and toxic industrial chemicals. This funding aims to elucidate toxicity mechanisms, explore new toxic exposure manifestations, and identify targets for therapeutic development. Proposals should generate data relevant to understanding these toxic threats, with applications due by 5 PM local time. Optional Letters of Intent are encouraged 30 days prior to the proposal deadline.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The Rooted Pathways Program, initiated by First Peoples Fund, offers essential support to Native-led arts organizations, fostering their growth and stability. This funding empowers these organizations to thrive in their missions, providing unrestricted operating support and participation in a Learning Cohort. Eligible applicants include Native nonprofits and collectives with budgets under $500,000, and the program aims to uplift artists from U.S. federally recognized tribes. This initiative is part of the Wallace Foundation's broader commitment to enhancing well-being in the arts.

The NCI Pathway to Independence Award (K99/R00) aims to support early-stage postdoctoral researchers transitioning to independent faculty positions. This initiative focuses on talented individuals with doctoral degrees in research or clinical fields, providing essential NCI funding during this key career juncture. Researchers engaged in cancer control, prevention, and data sciences are encouraged to apply for this opportunity, which emphasizes experimental studies with human participants, thus aligning with NIH's clinical trial definitions.

The Trans Justice Funding Project (TJFP) provides grants to grassroots trans-led organizations in the U.S. and territories, focusing on those with budgets under $250,000. TJFP supports initiatives that address varying needs within trans communities, including health, legal aid, and mutual aid projects. The organization prioritizes groups led by trans people of color and emphasizes the importance of centering marginalized voices in the fight for trans justice.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

This funding opportunity aims to advance mechanistic research for precision probiotic therapies. It invites R33 applications focused on characterizing individual differences in probiotic responses, identifying responder subgroups, and enhancing clinical outcomes. The goal is to develop strategies addressing barriers to effective probiotic use, accounting for human variability. Proposals should include innovative studies using animal models or human subjects, supported by preliminary data to test biological patterns and their effects on health outcomes.

This grant opportunity from the NIH aims to enhance mechanistic research on precision probiotic therapies through a biphasic R61/R33 award mechanism. It encourages innovative studies to identify specific biological factors influencing probiotic responses, thereby improving clinical outcomes. The program supports up to five years of research, with the initial phase focused on discovering unique host characteristics and the second phase assessing improvements in probiotic efficacy through rigorous studies.

The Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program, funded by the NIH, aims to enhance the biomedical research landscape by supporting resource-limited organizations. It targets domestic institutions with limited research resources and few doctoral students in biomedical fields, promoting broader participation in research and boosting administrative capacities for sponsored programs. Applications are due by 5:00 PM local time of the applicant organization, ensuring timely submissions.

The Lasker Clinical Research Scholars Program supports early-career clinical researchers aiming to enhance human health. It provides a unique opportunity to bridge NIH's intramural and extramural research environments over two phases: an initial 5-7 year tenure-track position at NIH followed by up to 3 years of extramural support. This program is designed to cultivate the next generation of leaders in clinical research and foster innovative health solutions.

The NIH is seeking innovative computational approaches to enhance the curation of biomedical research assets at scale. This initiative aims to accelerate access to secure datasets and computational models, facilitating transformative discoveries in biomedical science. Key deadlines for applications range from January 2025 to January 2027, covering standard, renewal, and AIDS-related grants. Applicants are encouraged to submit Letters of Intent 30 days prior to application deadlines to ensure a streamlined review process.

The High-End Instrumentation (HEI) Grant Program, offered by the NIH, invites applications for purchasing or upgrading high-end, specialized instruments, with a minimum award of $750,001 and a maximum of $2,000,000. This program supports NIH investigators aiming to enhance their research capabilities through advanced technologies such as mass spectrometers and electron microscopes. Applications must be submitted by 5:00 pm local time of the applicant organization.

The Shared Instrumentation Grant (SIG) Program supports NIH-funded investigators in acquiring high-cost, specialized instruments, with a minimum award of $50,000 and a maximum of $750,000. Eligible instruments include light microscopes, mass spectrometers, and DNA sequencers, among others. This program aims to enhance research capabilities by enabling the purchase or upgrade of essential equipment for scientific advancement.

The Limited Competition: Basic Instrumentation Grant (BIG) Program offers funding to NIH-supported researchers for purchasing specialized instruments or integrated systems, with minimum awards of $25,000 and maximum awards reaching $350,000. Eligibility is restricted to institutions that have not received significant S10 funding in recent years. This program aims to enhance research capabilities by providing access to essential technology, thereby fostering scientific innovation and collaboration within the NIH community.

This Funding Opportunity Announcement (FOA) aims to advance the identification and evaluation of candidate biomarkers for neurological and neuromuscular disorders. By facilitating the clinical development of neurotherapeutics, the FOA encourages research that includes both animal studies and preliminary human evaluations. The ultimate goal is to produce biomarkers ready for rigorous analytical and clinical validation, enhancing the effectiveness of treatments in clinical practice.

This funding opportunity invites applications for pilot projects focused on understudied proteins linked to rare diseases. The goal is to generate preliminary data and tools related to these proteins, which belong to druggable families with known rare disease associations. By supporting innovative research, this initiative aims to facilitate the characterization of these proteins, ultimately contributing to advancements in understanding and treating rare diseases.

This funding opportunity invites renewal applications for existing NINDS-supported clinical trial cooperative agreements (U01) that require additional time and resources. The National Institute of Neurological Disorders and Stroke (NINDS) expects applicants to request only what is necessary for trial completion, without introducing new aims. Discussions with NINDS prior to submission are encouraged. Eligible applications must be renewals of previously approved cooperative agreements under specified NIH funding announcements.